This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein, His Tag&Tag Free
catalog :
IT8-H52W4
quantity :
1 mg, 100 ug
price :
2880 USD, 410 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
IT8-H52W4
product name :
Human Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein, His Tag&Tag Free
quantity :
1 mg, 100 ug
price :
2880 USD, 410 USD
quantity & price :
$410/100ug,$2880/1mg (250ug × 4)
target :
Integrin alpha V beta 8
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free (IT8-H52W4) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Glu 43 - Arg 684 (ITGB8) (Accession # NP_002201.1 (ITGAV) & NP_002205.1 (ITGB8)).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM NaCl, pH8.0. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.
References :
(1) Moyle, M. et al., 1991, J. Biol. Chem. 266:19650-8.
(2) Nishimura SL., et al., 1994, J Biol Chem. 269(46):28708-15.
(3) Araya, J. et al., 2006, Am. J. Pathol. 169:405-15.
(4) Mu,D.et al.,2002, J. Cell Biol.157:493-507.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments